MedTrace Logo

188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas

NCT01126463 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-08-02

No results posted yet for this study

Summary

This study is to determine the maximum tolerated dose and the recommended 188Re-SSS Lipiodol activity for hepatic intra-arterial injection in patients with hepato-cellular carcinoma. The new radioactive isotope 188Rhenium associated with Lipiodol is expected to reduce the radioprotection constraints and hence the duration of the hospitalisation in a protected room from 8 to 1 day.

Conditions

  • Hepatocellular Carcinomas

Interventions

DRUG

188Re-SSS Lipiodol

Hepatic Intra-Arterial Administration of radio-active lipiodol.

Sponsors & Collaborators

  • Rennes University Hospital

    collaborator OTHER

  • Center Eugene Marquis

    lead OTHER

Principal Investigators

  • Etienne GARIN, MD, PhD · Centre Eugene Marquis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-26
Primary Completion
2019-08-06
Completion
2019-08-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126463 on ClinicalTrials.gov